GlassScriptPhysician profile
Amanda Camel
NPI 1376064550
$1,240.47
in general payments reported to CMS, 2019-2025
24 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $116 · 2024: $583 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $155.05 | 2024-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $136.72 | 2023-2025 | Acthar |
| Abbvie INC. | $114.44 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $110.06 | 2023-2025 | Triptodur, Triptodur |
| Genzyme Corporation | $85.77 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.40 | 2023-2025 | Eohilia, Gattex |
| Tolmar, INC. | $62.61 | 2025 | Fensolvi |
| Kyowa Kirin, INC. | $54.12 | 2024-2025 | Crysvita |
| Neurocrine Biosciences, INC. | $48.80 | 2025 | |
| Tandem Diabetes Care, INC. | $43.20 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $41.58 | 2024 | Strensiq, Ultomiris |
| Ipsen Biopharmaceuticals, INC | $36.51 | 2024 | Bylvay |
| Biomarin Pharmaceutical INC. | $30.21 | 2024 | Voxzogo 1.2mg |
| Novartis Pharmaceuticals Corporation | $25.80 | 2024 | |
| Alcresta Therapeutics, INC. | $25.54 | 2024 | Relizorb |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $24.29 | 2024 | Livmarli |
| Ascendis Pharma Endocrinology INC | $24.00 | 2024 | |
| Dexcom, INC. | $23.92 | 2025 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $22.87 | 2025 | Daybue |
| Xeris Pharmaceuticals, INC. | $22.68 | 2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $18.84 | 2025 | |
| Endo Pharmaceuticals INC. | $18.11 | 2023 | Supprelin |
| Apellis Pharmaceuticals, INC. | $17.09 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $12.86 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Camel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.